Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Anti-claudin18a2 chimeric antigen receptor, its modified T cell and T cell preparation method and application

A technology of chimeric antigen receptors and cells, which is applied in the field of genetic engineering, can solve problems such as the difficulty of technology improvement, and achieve the effects of enhancing immunity, expanding the attack range, and simplifying procedures

Active Publication Date: 2022-04-05
SHANDONG XINRUI BIOTECH CO LTD
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The applicant found in long-term research that the gene drug prepared by simply knocking out the PD-1 gene in T cells needs to be further improved in the treatment of digestive system tumors, especially gastric cancer. However, the technical improvement at the bottleneck stage It is very difficult and also a technical problem in this field

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-claudin18a2 chimeric antigen receptor, its modified T cell and T cell preparation method and application
  • Anti-claudin18a2 chimeric antigen receptor, its modified T cell and T cell preparation method and application
  • Anti-claudin18a2 chimeric antigen receptor, its modified T cell and T cell preparation method and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0044] Anti-Claudin18A2 chimeric antigen receptor, including sequentially linked CD8αLeader, Claudin18A2 antigen-binding region, CD8 hinge region and transmembrane region, 4-1BB and CD28 co-stimulatory region, CD3ζ signal transduction region, the complete nucleic acid sequence is shown in the appendix SEQ ID NO.1.

[0045] Module sequence of CAR-Claudin18A2

[0046] (1) CD8α Leader (SEQ ID NO.2)

[0047] (2) Claudin18A2 antigen-binding region (SEQ ID NO.3)

[0048] (3) CD8Hinge region (SEQ ID NO.4)

[0049] (4) CD8 transmembrane region (SEQ ID NO.5)

[0050] (5) CD28 co-stimulatory region (SEQ ID NO.6)

[0051] (6) 4-1BB co-stimulatory region (SEQ ID NO.7)

[0052] (7) CD3ζ signaling region (SEQ ID NO.8).

Embodiment 2

[0054] The anti-Claudin18A2 chimeric antigen receptor is prepared by a method comprising the following steps:

[0055] (1) According to the order of Example 1 CD8α Leader, Claudin18A2 antigen binding region, CD8 Hinge region and transmembrane region, 4-1BB and CD28 co-stimulatory region, CD3ζ signal transduction region entrusted to Beijing Biomed Gene Technology Co., Ltd. to synthesize Its entire expression cassette (Claudin18A2 module indicated figure 1 ), and inserted into the cloning vector pUC57, the resulting product was named pUC-Claudin18A2,;

[0056](2) Carry out double enzyme digestion of pUC-Claudin18A2, use agar electrophoresis to cut off the agar part containing the Claudin18A2 DNA fragment, use the DNA extraction kit sol solution to treat, pass through the DF column and discard the filtrate, rinse the DF column, empty and elute DF column, and the centrifuged matter was collected to obtain a purified Claudin18A2 DNA fragment. In this example, the detailed steps ...

Embodiment 3

[0058] Construction of pLent-EF1α-CAR-Claudin18A2 expression vector

[0059] The recombinant expression vector was prepared by the following steps: the entire expression frame was synthesized according to the CD8α Leader, Claudin18A2 antigen-binding region, CD8 Hinge region and transmembrane region, 4-1BB and CD28 co-stimulatory region, and CD3ζ signal transduction region and inserted into pLent -EF1α vector (purchased from Vigene company) BamHI-NotI site (such as figure 2 ), transformed into E.coli (Top10), after the sequence was correct, the plasmid was extracted using the plasmid extraction kit of OMEGA Company, and the recombinant expression vector pLent-EF1α-CAR-Claudin18A2 was obtained.

[0060] The detailed steps of recombinant plasmid pLent-EF1α-CAR-Claudin18A2 are as follows:

[0061] According to CD8αLeader, Claudin18A2 antigen-binding region, CD8 Hinge region and transmembrane region, 4-1BB and CD28 costimulatory region, CD3ζ signal transduction region commissioned...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention discloses an anti-Claudin18A2 chimeric antigen receptor, its modified T cells and T cell preparation methods and uses, wherein the anti-Claudin18A2 chimeric antigen receptor includes sequentially connected CD8αLeader, Claudin18A2 antigen-binding region, and CD8 Hinge region and the transmembrane region, the co-stimulatory region of 4-1BB and CD28, and the signaling region of CD3ζ. The present invention creatively selects the target of Claudin18A2, and simultaneously knocks out the PD‑1 protein in T cells, so that the modified T cells can improve the therapeutic effect on digestive system tumors, especially gastric cancer.

Description

technical field [0001] The invention relates to the technical field of genetic engineering, in particular to an anti-Claudin18A2 chimeric antigen receptor, a T cell modified by the same, and a method for preparing and using the T cell. Background technique [0002] PD-1 (programmed death receptor 1, programmed death 1) is a 55KD transmembrane protein that belongs to the immunoglobulin superfamily. There is only one IgV-like region in the extracellular region, two tyrosine residues in the cytoplasmic region, and one ITIM (immunoreceptor tryosine-based inhibitory motif) at the tail. PD-1 can be expressed on activated T cells, B cells and myeloid cells, as well as CD4-CD8-thymocytes. PD-1 has two ligands, PD-L1 (B7-H1) and PD-L2 (B7-DC), both of which are new members of the B7 family. PD-1 is an immunosuppressive receptor that interacts with its ligands PD-L1 and PD-L2 to transmit inhibitory signals and play a negative regulatory role in the immune response. The combination ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K19/00C12N5/10C12N15/867A61K35/17A61P35/00
CPCA61P35/00A61K35/17C12N15/86C07K14/7051C07K14/70521C07K16/28C07K2317/76C07K2319/33C12N2740/15043
Inventor 刘明录王立新韩庆梅万磊卢永灿张传鹏刘敏马洪华金海锋冯建海
Owner SHANDONG XINRUI BIOTECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com